The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HER2DX prognostic value in older patients with HER2-positive early breast cancer: A correlative analysis from the RESPECT phase III trial.
 
Kazuki Nozawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Lilly Japan
 
Masataka Sawaki
No Relationships to Disclose
 
Yukari Uemura
Honoraria - Chugai Pharma
Speakers' Bureau - Lilly; Pfizer
 
Michiko Tsuneizumi
No Relationships to Disclose
 
Toshimi Takano
Honoraria - Daiichi Sankyo; Lilly
 
Naomi Gondo
No Relationships to Disclose
 
Fumikata Hara
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
 
Michiko Harao
No Relationships to Disclose
 
Mercedes Marín-Aguilera
Employment - Reveal Genomics
 
Patricia Villagrasa
Employment - Reveal Genomics
 
Aleix Prat
Employment - Reveal Genomics
Leadership - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - AstraZeneca; Daiichi Sankyo; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Novartis; Oncolytics; Pfizer; Roche
Research Funding - AstraZeneca; Daiichi Sankyo; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; TNBC-DX
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)